Rationale for enteroviral vaccination and antiviral therapies in human type 1 diabetes
Jessica L. Dunne(Sanofi (United States)), Alberto Pugliese(University of Miami), Heikki Hyöty(Tampere University of Applied Sciences), Richard A. Insel(Breakthrough T1D), Noel G. Morgan(University of Exeter), Sarah J. Richardson(University of Exeter), Mark A. Atkinson(University of Florida), Malin Flodström‐Tullberg(Karolinska University Hospital), Maria E. Craig(New South Wales Department of Health), Knut Dahl‐Jørgensen(Oslo University Hospital), Richard E. Lloyd(Baylor College of Medicine), Åke Lernmark(Lund University)
Cited by 92
Related Papers
Type 1 diabetes
|The Lancet|2013|2.7k
Type 1 diabetes: new perspectives on disease pathogenesis and treatment
|The Lancet|2001|1.5k
Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association
|Diabetes Care|2015|1.2k
The Pathogenesis of Insulin-Dependent Diabetes Mellitus
|New England Journal of Medicine|1994|1.1k